nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—ABCC2—esophageal cancer	0.523	1	CbGaD
Olmesartan—SLCO1B3—Methotrexate—esophageal cancer	0.0976	0.263	CbGbCtD
Olmesartan—ABCC2—Carboplatin—esophageal cancer	0.09	0.242	CbGbCtD
Olmesartan—ABCC2—Cisplatin—esophageal cancer	0.0769	0.207	CbGbCtD
Olmesartan—SLCO1B1—Methotrexate—esophageal cancer	0.0568	0.153	CbGbCtD
Olmesartan—ABCC2—Methotrexate—esophageal cancer	0.0499	0.134	CbGbCtD
Olmesartan—SLCO1B3—Recycling of bile acids and salts—SLC10A2—esophageal cancer	0.00296	0.0718	CbGpPWpGaD
Olmesartan—Malabsorption—Methotrexate—esophageal cancer	0.00231	0.0377	CcSEcCtD
Olmesartan—SLCO1B1—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00214	0.0519	CbGpPWpGaD
Olmesartan—SLCO1B1—Recycling of bile acids and salts—SLC10A2—esophageal cancer	0.00199	0.0483	CbGpPWpGaD
Olmesartan—SLCO1B3—Bile acid and bile salt metabolism—SLC10A2—esophageal cancer	0.00155	0.0375	CbGpPWpGaD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.0014	0.0339	CbGpPWpGaD
Olmesartan—SLCO1B1—Irinotecan Pathway—ABCC2—esophageal cancer	0.00137	0.0332	CbGpPWpGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00132	0.0319	CbGpPWpGaD
Olmesartan—ABCC2—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00121	0.0293	CbGpPWpGaD
Olmesartan—Blood potassium decreased—Capecitabine—esophageal cancer	0.00119	0.0193	CcSEcCtD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00117	0.0284	CbGpPWpGaD
Olmesartan—SLCO1B1—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00114	0.0275	CbGpPWpGaD
Olmesartan—SLCO1B1—Bile acid and bile salt metabolism—SLC10A2—esophageal cancer	0.00104	0.0252	CbGpPWpGaD
Olmesartan—Diabetic—Methotrexate—esophageal cancer	0.00101	0.0164	CcSEcCtD
Olmesartan—Telmisartan—ABCC2—esophageal cancer	0.001	0.325	CrCbGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000804	0.0195	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000804	0.0195	CbGpPWpGaD
Olmesartan—Hypertriglyceridaemia—Capecitabine—esophageal cancer	0.000786	0.0128	CcSEcCtD
Olmesartan—Rhinorrhoea—Cisplatin—esophageal cancer	0.000756	0.0123	CcSEcCtD
Olmesartan—Infection—Carboplatin—esophageal cancer	0.00074	0.012	CcSEcCtD
Olmesartan—AGTR1—Arf6 trafficking events—CTNNA1—esophageal cancer	0.000713	0.0173	CbGpPWpGaD
Olmesartan—Respiratory distress—Capecitabine—esophageal cancer	0.00071	0.0116	CcSEcCtD
Olmesartan—Blood triglycerides increased—Capecitabine—esophageal cancer	0.000689	0.0112	CcSEcCtD
Olmesartan—Appetite absent—Methotrexate—esophageal cancer	0.000675	0.011	CcSEcCtD
Olmesartan—Bone marrow depression—Capecitabine—esophageal cancer	0.000668	0.0109	CcSEcCtD
Olmesartan—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.000668	0.0109	CcSEcCtD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.000662	0.016	CbGpPWpGaD
Olmesartan—Laryngeal pain—Capecitabine—esophageal cancer	0.000662	0.0108	CcSEcCtD
Olmesartan—Hyperuricaemia—Cisplatin—esophageal cancer	0.00066	0.0107	CcSEcCtD
Olmesartan—Pain—Carboplatin—esophageal cancer	0.000637	0.0104	CcSEcCtD
Olmesartan—AGTR1—ACE Inhibitor Pathway—NOS3—esophageal cancer	0.000635	0.0154	CbGpPWpGaD
Olmesartan—Blood uric acid increased—Cisplatin—esophageal cancer	0.000623	0.0101	CcSEcCtD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.000622	0.0151	CbGpPWpGaD
Olmesartan—Candesartan—PTGS1—esophageal cancer	0.000612	0.198	CrCbGaD
Olmesartan—Irbesartan—PTGS1—esophageal cancer	0.000612	0.198	CrCbGaD
Olmesartan—ABCC2—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000602	0.0146	CbGpPWpGaD
Olmesartan—Hyperkalaemia—Cisplatin—esophageal cancer	0.000601	0.00979	CcSEcCtD
Olmesartan—Body temperature increased—Carboplatin—esophageal cancer	0.000589	0.00958	CcSEcCtD
Olmesartan—Rhinorrhoea—Capecitabine—esophageal cancer	0.000557	0.00907	CcSEcCtD
Olmesartan—Bone marrow depression—Methotrexate—esophageal cancer	0.000498	0.0081	CcSEcCtD
Olmesartan—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000496	0.00808	CcSEcCtD
Olmesartan—Haemolytic anaemia—Cisplatin—esophageal cancer	0.000492	0.00801	CcSEcCtD
Olmesartan—Renal failure acute—Cisplatin—esophageal cancer	0.000481	0.00783	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—ALDH3A1—esophageal cancer	0.000477	0.0116	CbGpPWpGaD
Olmesartan—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000477	0.00777	CcSEcCtD
Olmesartan—Bone pain—Capecitabine—esophageal cancer	0.000471	0.00767	CcSEcCtD
Olmesartan—AGTR1—Arf6 signaling events—MET—esophageal cancer	0.000456	0.011	CbGpPWpGaD
Olmesartan—Hyponatraemia—Cisplatin—esophageal cancer	0.000446	0.00726	CcSEcCtD
Olmesartan—Influenza like illness—Capecitabine—esophageal cancer	0.000438	0.00713	CcSEcCtD
Olmesartan—Face oedema—Cisplatin—esophageal cancer	0.000429	0.00698	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—BLVRB—esophageal cancer	0.000425	0.0103	CbGpPWpGaD
Olmesartan—Blood creatinine increased—Cisplatin—esophageal cancer	0.000416	0.00678	CcSEcCtD
Olmesartan—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000406	0.00661	CcSEcCtD
Olmesartan—Hypokalaemia—Cisplatin—esophageal cancer	0.000404	0.00658	CcSEcCtD
Olmesartan—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.0004	0.00651	CcSEcCtD
Olmesartan—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000399	0.00967	CbGpPWpGaD
Olmesartan—Nasopharyngitis—Cisplatin—esophageal cancer	0.000397	0.00647	CcSEcCtD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00038	0.00922	CbGpPWpGaD
Olmesartan—Sleep disorder—Capecitabine—esophageal cancer	0.000378	0.00616	CcSEcCtD
Olmesartan—Diabetes mellitus—Capecitabine—esophageal cancer	0.000377	0.00613	CcSEcCtD
Olmesartan—Pancreatitis—Cisplatin—esophageal cancer	0.000376	0.00613	CcSEcCtD
Olmesartan—Gastroenteritis—Capecitabine—esophageal cancer	0.00037	0.00602	CcSEcCtD
Olmesartan—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000369	0.00601	CcSEcCtD
Olmesartan—Telmisartan—ABCB1—esophageal cancer	0.000369	0.12	CrCbGaD
Olmesartan—Pancytopenia—Cisplatin—esophageal cancer	0.000365	0.00594	CcSEcCtD
Olmesartan—ABCC2—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.000363	0.0088	CbGpPWpGaD
Olmesartan—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000363	0.00591	CcSEcCtD
Olmesartan—Hyperuricaemia—Methotrexate—esophageal cancer	0.000362	0.00589	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—PRDX1—esophageal cancer	0.000362	0.00876	CbGpPWpGaD
Olmesartan—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.000355	0.00578	CcSEcCtD
Olmesartan—Renal failure acute—Capecitabine—esophageal cancer	0.000355	0.00577	CcSEcCtD
Olmesartan—Vasculitis—Methotrexate—esophageal cancer	0.000344	0.0056	CcSEcCtD
Olmesartan—Blood uric acid increased—Methotrexate—esophageal cancer	0.000342	0.00557	CcSEcCtD
Olmesartan—Arthritis—Capecitabine—esophageal cancer	0.000337	0.00549	CcSEcCtD
Olmesartan—Renal failure—Cisplatin—esophageal cancer	0.000337	0.00548	CcSEcCtD
Olmesartan—Lethargy—Capecitabine—esophageal cancer	0.000334	0.00544	CcSEcCtD
Olmesartan—Hyponatraemia—Capecitabine—esophageal cancer	0.000329	0.00535	CcSEcCtD
Olmesartan—Pain in extremity—Capecitabine—esophageal cancer	0.000328	0.00533	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—SLC39A6—esophageal cancer	0.000322	0.00781	CbGpPWpGaD
Olmesartan—Face oedema—Capecitabine—esophageal cancer	0.000316	0.00515	CcSEcCtD
Olmesartan—Aplastic anaemia—Methotrexate—esophageal cancer	0.000315	0.00513	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—ABCB1—esophageal cancer	0.00031	0.00752	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—ADH7—esophageal cancer	0.000307	0.00745	CbGpPWpGaD
Olmesartan—Blood creatinine increased—Capecitabine—esophageal cancer	0.000307	0.00499	CcSEcCtD
Olmesartan—Urinary tract disorder—Cisplatin—esophageal cancer	0.000304	0.00494	CcSEcCtD
Olmesartan—Connective tissue disorder—Cisplatin—esophageal cancer	0.000302	0.00492	CcSEcCtD
Olmesartan—Urethral disorder—Cisplatin—esophageal cancer	0.000301	0.0049	CcSEcCtD
Olmesartan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000299	0.00487	CcSEcCtD
Olmesartan—Hypokalaemia—Capecitabine—esophageal cancer	0.000298	0.00485	CcSEcCtD
Olmesartan—Candesartan—ABCB1—esophageal cancer	0.000297	0.0964	CrCbGaD
Olmesartan—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000295	0.0048	CcSEcCtD
Olmesartan—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000295	0.0048	CcSEcCtD
Olmesartan—Nasopharyngitis—Capecitabine—esophageal cancer	0.000293	0.00477	CcSEcCtD
Olmesartan—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000289	0.0047	CcSEcCtD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000284	0.00688	CbGpPWpGaD
Olmesartan—Influenza—Capecitabine—esophageal cancer	0.000283	0.00461	CcSEcCtD
Olmesartan—Diabetes mellitus—Methotrexate—esophageal cancer	0.00028	0.00456	CcSEcCtD
Olmesartan—Mediastinal disorder—Cisplatin—esophageal cancer	0.000277	0.00451	CcSEcCtD
Olmesartan—Angina pectoris—Capecitabine—esophageal cancer	0.000276	0.00449	CcSEcCtD
Olmesartan—Arrhythmia—Cisplatin—esophageal cancer	0.000275	0.00447	CcSEcCtD
Olmesartan—Bronchitis—Capecitabine—esophageal cancer	0.000272	0.00443	CcSEcCtD
Olmesartan—Alopecia—Cisplatin—esophageal cancer	0.000272	0.00442	CcSEcCtD
Olmesartan—Pancytopenia—Capecitabine—esophageal cancer	0.000269	0.00438	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—esophageal cancer	0.000268	0.00649	CbGpPWpGaD
Olmesartan—Malnutrition—Cisplatin—esophageal cancer	0.000268	0.00436	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—GNG7—esophageal cancer	0.000266	0.00646	CbGpPWpGaD
Olmesartan—Neutropenia—Capecitabine—esophageal cancer	0.000265	0.00431	CcSEcCtD
Olmesartan—Renal failure acute—Methotrexate—esophageal cancer	0.000264	0.0043	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000263	0.00428	CcSEcCtD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00026	0.00629	CbGpPWpGaD
Olmesartan—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000258	0.00421	CcSEcCtD
Olmesartan—Muscle spasms—Cisplatin—esophageal cancer	0.000257	0.00419	CcSEcCtD
Olmesartan—Hyperglycaemia—Capecitabine—esophageal cancer	0.000255	0.00416	CcSEcCtD
Olmesartan—Pneumonia—Capecitabine—esophageal cancer	0.000254	0.00413	CcSEcCtD
Olmesartan—Infestation NOS—Capecitabine—esophageal cancer	0.000252	0.00411	CcSEcCtD
Olmesartan—Infestation—Capecitabine—esophageal cancer	0.000252	0.00411	CcSEcCtD
Olmesartan—Vision blurred—Cisplatin—esophageal cancer	0.000252	0.00411	CcSEcCtD
Olmesartan—Lethargy—Methotrexate—esophageal cancer	0.000249	0.00405	CcSEcCtD
Olmesartan—Ill-defined disorder—Cisplatin—esophageal cancer	0.000248	0.00404	CcSEcCtD
Olmesartan—Renal failure—Capecitabine—esophageal cancer	0.000248	0.00404	CcSEcCtD
Olmesartan—Anaemia—Cisplatin—esophageal cancer	0.000247	0.00403	CcSEcCtD
Olmesartan—Jaundice—Capecitabine—esophageal cancer	0.000246	0.004	CcSEcCtD
Olmesartan—Urinary tract infection—Capecitabine—esophageal cancer	0.000245	0.00399	CcSEcCtD
Olmesartan—Malaise—Cisplatin—esophageal cancer	0.000241	0.00393	CcSEcCtD
Olmesartan—Haematuria—Capecitabine—esophageal cancer	0.000241	0.00392	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00024	0.00581	CbGpPWpGaD
Olmesartan—Leukopenia—Cisplatin—esophageal cancer	0.00024	0.0039	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNG7—esophageal cancer	0.000238	0.00577	CbGpPWpGaD
Olmesartan—Agranulocytosis—Capecitabine—esophageal cancer	0.000236	0.00383	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.000232	0.00562	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 signaling events—EGFR—esophageal cancer	0.000231	0.0056	CbGpPWpGaD
Olmesartan—Myalgia—Cisplatin—esophageal cancer	0.000228	0.00371	CcSEcCtD
Olmesartan—Rhinitis—Capecitabine—esophageal cancer	0.000227	0.0037	CcSEcCtD
Olmesartan—Anxiety—Cisplatin—esophageal cancer	0.000227	0.0037	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000226	0.00368	CcSEcCtD
Olmesartan—Discomfort—Cisplatin—esophageal cancer	0.000225	0.00366	CcSEcCtD
Olmesartan—Pharyngitis—Capecitabine—esophageal cancer	0.000225	0.00366	CcSEcCtD
Olmesartan—Urinary tract disorder—Capecitabine—esophageal cancer	0.000224	0.00364	CcSEcCtD
Olmesartan—Oedema peripheral—Capecitabine—esophageal cancer	0.000223	0.00363	CcSEcCtD
Olmesartan—Connective tissue disorder—Capecitabine—esophageal cancer	0.000223	0.00362	CcSEcCtD
Olmesartan—Urethral disorder—Capecitabine—esophageal cancer	0.000222	0.00362	CcSEcCtD
Olmesartan—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00022	0.00357	CcSEcCtD
Olmesartan—Anaphylactic shock—Cisplatin—esophageal cancer	0.000218	0.00355	CcSEcCtD
Olmesartan—Oedema—Cisplatin—esophageal cancer	0.000218	0.00355	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—ANXA1—esophageal cancer	0.000218	0.00529	CbGpPWpGaD
Olmesartan—Infection—Cisplatin—esophageal cancer	0.000217	0.00353	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.000215	0.00522	CbGpPWpGaD
Olmesartan—Nervous system disorder—Cisplatin—esophageal cancer	0.000214	0.00349	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—esophageal cancer	0.000214	0.00519	CbGpPWpGaD
Olmesartan—Thrombocytopenia—Cisplatin—esophageal cancer	0.000214	0.00348	CcSEcCtD
Olmesartan—Tachycardia—Cisplatin—esophageal cancer	0.000213	0.00347	CcSEcCtD
Olmesartan—Skin disorder—Cisplatin—esophageal cancer	0.000212	0.00345	CcSEcCtD
Olmesartan—Hyperhidrosis—Cisplatin—esophageal cancer	0.000211	0.00344	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—SST—esophageal cancer	0.00021	0.00508	CbGpPWpGaD
Olmesartan—Eosinophilia—Methotrexate—esophageal cancer	0.000209	0.0034	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—CASP8—esophageal cancer	0.000208	0.00505	CbGpPWpGaD
Olmesartan—Anorexia—Cisplatin—esophageal cancer	0.000208	0.00339	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—NFE2L2—esophageal cancer	0.000208	0.00503	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—GHRL—esophageal cancer	0.000207	0.00501	CbGpPWpGaD
Olmesartan—Pancreatitis—Methotrexate—esophageal cancer	0.000207	0.00336	CcSEcCtD
Olmesartan—Angiopathy—Capecitabine—esophageal cancer	0.000206	0.00335	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.000204	0.00495	CbGpPWpGaD
Olmesartan—Mediastinal disorder—Capecitabine—esophageal cancer	0.000204	0.00332	CcSEcCtD
Olmesartan—Hypotension—Cisplatin—esophageal cancer	0.000204	0.00332	CcSEcCtD
Olmesartan—Arrhythmia—Capecitabine—esophageal cancer	0.000202	0.0033	CcSEcCtD
Olmesartan—Alopecia—Capecitabine—esophageal cancer	0.0002	0.00326	CcSEcCtD
Olmesartan—Pancytopenia—Methotrexate—esophageal cancer	0.0002	0.00326	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000199	0.00324	CcSEcCtD
Olmesartan—Mental disorder—Capecitabine—esophageal cancer	0.000199	0.00323	CcSEcCtD
Olmesartan—Malnutrition—Capecitabine—esophageal cancer	0.000197	0.00321	CcSEcCtD
Olmesartan—Neutropenia—Methotrexate—esophageal cancer	0.000197	0.00321	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000196	0.00319	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.000195	0.00473	CbGpPWpGaD
Olmesartan—Erectile dysfunction—Methotrexate—esophageal cancer	0.000194	0.00316	CcSEcCtD
Olmesartan—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000192	0.00313	CcSEcCtD
Olmesartan—Losartan—ABCB1—esophageal cancer	0.000192	0.0621	CrCbGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000191	0.00462	CbGpPWpGaD
Olmesartan—Back pain—Capecitabine—esophageal cancer	0.000191	0.00311	CcSEcCtD
Olmesartan—Decreased appetite—Cisplatin—esophageal cancer	0.00019	0.00309	CcSEcCtD
Olmesartan—Muscle spasms—Capecitabine—esophageal cancer	0.00019	0.00309	CcSEcCtD
Olmesartan—Pneumonia—Methotrexate—esophageal cancer	0.000189	0.00308	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000189	0.00307	CcSEcCtD
Olmesartan—Infestation—Methotrexate—esophageal cancer	0.000188	0.00306	CcSEcCtD
Olmesartan—Infestation NOS—Methotrexate—esophageal cancer	0.000188	0.00306	CcSEcCtD
Olmesartan—Pain—Cisplatin—esophageal cancer	0.000187	0.00304	CcSEcCtD
Olmesartan—Vision blurred—Capecitabine—esophageal cancer	0.000186	0.00303	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.000185	0.00448	CbGpPWpGaD
Olmesartan—Renal failure—Methotrexate—esophageal cancer	0.000185	0.00301	CcSEcCtD
Olmesartan—Ill-defined disorder—Capecitabine—esophageal cancer	0.000183	0.00298	CcSEcCtD
Olmesartan—Anaemia—Capecitabine—esophageal cancer	0.000182	0.00297	CcSEcCtD
Olmesartan—Feeling abnormal—Cisplatin—esophageal cancer	0.00018	0.00293	CcSEcCtD
Olmesartan—Haematuria—Methotrexate—esophageal cancer	0.000179	0.00292	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—CYP2A6—esophageal cancer	0.000179	0.00433	CbGpPWpGaD
Olmesartan—Malaise—Capecitabine—esophageal cancer	0.000178	0.0029	CcSEcCtD
Olmesartan—Vertigo—Capecitabine—esophageal cancer	0.000177	0.00288	CcSEcCtD
Olmesartan—Syncope—Capecitabine—esophageal cancer	0.000177	0.00288	CcSEcCtD
Olmesartan—Leukopenia—Capecitabine—esophageal cancer	0.000177	0.00287	CcSEcCtD
Olmesartan—Agranulocytosis—Methotrexate—esophageal cancer	0.000175	0.00285	CcSEcCtD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000174	0.00423	CbGpPWpGaD
Olmesartan—Palpitations—Capecitabine—esophageal cancer	0.000174	0.00284	CcSEcCtD
Olmesartan—Loss of consciousness—Capecitabine—esophageal cancer	0.000173	0.00282	CcSEcCtD
Olmesartan—Body temperature increased—Cisplatin—esophageal cancer	0.000173	0.00281	CcSEcCtD
Olmesartan—Cough—Capecitabine—esophageal cancer	0.000172	0.0028	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00017	0.00413	CbGpPWpGaD
Olmesartan—Myalgia—Capecitabine—esophageal cancer	0.000168	0.00273	CcSEcCtD
Olmesartan—Chest pain—Capecitabine—esophageal cancer	0.000168	0.00273	CcSEcCtD
Olmesartan—Arthralgia—Capecitabine—esophageal cancer	0.000168	0.00273	CcSEcCtD
Olmesartan—Pharyngitis—Methotrexate—esophageal cancer	0.000167	0.00273	CcSEcCtD
Olmesartan—Anxiety—Capecitabine—esophageal cancer	0.000167	0.00272	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000167	0.00271	CcSEcCtD
Olmesartan—Urinary tract disorder—Methotrexate—esophageal cancer	0.000167	0.00271	CcSEcCtD
Olmesartan—Discomfort—Capecitabine—esophageal cancer	0.000166	0.0027	CcSEcCtD
Olmesartan—Urethral disorder—Methotrexate—esophageal cancer	0.000165	0.00269	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000162	0.00392	CbGpPWpGaD
Olmesartan—Oedema—Capecitabine—esophageal cancer	0.000161	0.00262	CcSEcCtD
Olmesartan—Infection—Capecitabine—esophageal cancer	0.00016	0.0026	CcSEcCtD
Olmesartan—Shock—Capecitabine—esophageal cancer	0.000158	0.00258	CcSEcCtD
Olmesartan—Nervous system disorder—Capecitabine—esophageal cancer	0.000158	0.00257	CcSEcCtD
Olmesartan—Thrombocytopenia—Capecitabine—esophageal cancer	0.000158	0.00257	CcSEcCtD
Olmesartan—Tachycardia—Capecitabine—esophageal cancer	0.000157	0.00256	CcSEcCtD
Olmesartan—Asthenia—Cisplatin—esophageal cancer	0.000157	0.00255	CcSEcCtD
Olmesartan—Skin disorder—Capecitabine—esophageal cancer	0.000156	0.00255	CcSEcCtD
Olmesartan—Hyperhidrosis—Capecitabine—esophageal cancer	0.000156	0.00253	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000155	0.00377	CbGpPWpGaD
Olmesartan—Anorexia—Capecitabine—esophageal cancer	0.000153	0.0025	CcSEcCtD
Olmesartan—Angiopathy—Methotrexate—esophageal cancer	0.000153	0.00249	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000152	0.00369	CbGpPWpGaD
Olmesartan—Mediastinal disorder—Methotrexate—esophageal cancer	0.000152	0.00247	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—esophageal cancer	0.000151	0.00365	CbGpPWpGaD
Olmesartan—Hypotension—Capecitabine—esophageal cancer	0.00015	0.00245	CcSEcCtD
Olmesartan—Diarrhoea—Cisplatin—esophageal cancer	0.000149	0.00243	CcSEcCtD
Olmesartan—Alopecia—Methotrexate—esophageal cancer	0.000149	0.00243	CcSEcCtD
Olmesartan—Mental disorder—Methotrexate—esophageal cancer	0.000148	0.00241	CcSEcCtD
Olmesartan—Malnutrition—Methotrexate—esophageal cancer	0.000147	0.00239	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000147	0.00239	CcSEcCtD
Olmesartan—Insomnia—Capecitabine—esophageal cancer	0.000146	0.00237	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000145	0.0035	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000144	0.0035	CbGpPWpGaD
Olmesartan—Back pain—Methotrexate—esophageal cancer	0.000142	0.00231	CcSEcCtD
Olmesartan—Dyspepsia—Capecitabine—esophageal cancer	0.000142	0.00231	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000141	0.00341	CbGpPWpGaD
Olmesartan—Decreased appetite—Capecitabine—esophageal cancer	0.00014	0.00228	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000139	0.00226	CcSEcCtD
Olmesartan—Vomiting—Cisplatin—esophageal cancer	0.000139	0.00226	CcSEcCtD
Olmesartan—Fatigue—Capecitabine—esophageal cancer	0.000139	0.00226	CcSEcCtD
Olmesartan—Vision blurred—Methotrexate—esophageal cancer	0.000138	0.00225	CcSEcCtD
Olmesartan—Rash—Cisplatin—esophageal cancer	0.000138	0.00224	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000138	0.00334	CbGpPWpGaD
Olmesartan—Constipation—Capecitabine—esophageal cancer	0.000138	0.00224	CcSEcCtD
Olmesartan—Pain—Capecitabine—esophageal cancer	0.000138	0.00224	CcSEcCtD
Olmesartan—Dermatitis—Cisplatin—esophageal cancer	0.000138	0.00224	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000137	0.00332	CbGpPWpGaD
Olmesartan—Ill-defined disorder—Methotrexate—esophageal cancer	0.000136	0.00222	CcSEcCtD
Olmesartan—Anaemia—Methotrexate—esophageal cancer	0.000136	0.00221	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000135	0.00328	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—GNG7—esophageal cancer	0.000134	0.00326	CbGpPWpGaD
Olmesartan—Feeling abnormal—Capecitabine—esophageal cancer	0.000133	0.00216	CcSEcCtD
Olmesartan—Malaise—Methotrexate—esophageal cancer	0.000132	0.00216	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000132	0.0032	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000132	0.0032	CbGpPWpGaD
Olmesartan—Vertigo—Methotrexate—esophageal cancer	0.000132	0.00215	CcSEcCtD
Olmesartan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000132	0.00214	CcSEcCtD
Olmesartan—Leukopenia—Methotrexate—esophageal cancer	0.000131	0.00214	CcSEcCtD
Olmesartan—Nausea—Cisplatin—esophageal cancer	0.00013	0.00211	CcSEcCtD
Olmesartan—Cough—Methotrexate—esophageal cancer	0.000128	0.00209	CcSEcCtD
Olmesartan—Urticaria—Capecitabine—esophageal cancer	0.000128	0.00208	CcSEcCtD
Olmesartan—Body temperature increased—Capecitabine—esophageal cancer	0.000127	0.00207	CcSEcCtD
Olmesartan—Abdominal pain—Capecitabine—esophageal cancer	0.000127	0.00207	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—TGFBR2—esophageal cancer	0.000125	0.00303	CbGpPWpGaD
Olmesartan—Arthralgia—Methotrexate—esophageal cancer	0.000125	0.00203	CcSEcCtD
Olmesartan—Myalgia—Methotrexate—esophageal cancer	0.000125	0.00203	CcSEcCtD
Olmesartan—Chest pain—Methotrexate—esophageal cancer	0.000125	0.00203	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000124	0.00202	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—HMOX1—esophageal cancer	0.000124	0.00299	CbGpPWpGaD
Olmesartan—Discomfort—Methotrexate—esophageal cancer	0.000124	0.00201	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000123	0.00298	CbGpPWpGaD
Olmesartan—Anaphylactic shock—Methotrexate—esophageal cancer	0.00012	0.00195	CcSEcCtD
Olmesartan—Infection—Methotrexate—esophageal cancer	0.000119	0.00194	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CXCL2—esophageal cancer	0.000118	0.00287	CbGpPWpGaD
Olmesartan—Nervous system disorder—Methotrexate—esophageal cancer	0.000118	0.00191	CcSEcCtD
Olmesartan—Thrombocytopenia—Methotrexate—esophageal cancer	0.000117	0.00191	CcSEcCtD
Olmesartan—Skin disorder—Methotrexate—esophageal cancer	0.000116	0.00189	CcSEcCtD
Olmesartan—Hyperhidrosis—Methotrexate—esophageal cancer	0.000116	0.00189	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000116	0.00281	CbGpPWpGaD
Olmesartan—Asthenia—Capecitabine—esophageal cancer	0.000115	0.00188	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000115	0.00279	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000114	0.00277	CbGpPWpGaD
Olmesartan—Anorexia—Methotrexate—esophageal cancer	0.000114	0.00186	CcSEcCtD
Olmesartan—Pruritus—Capecitabine—esophageal cancer	0.000114	0.00185	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—GDI2—esophageal cancer	0.000113	0.00273	CbGpPWpGaD
Olmesartan—Hypotension—Methotrexate—esophageal cancer	0.000112	0.00182	CcSEcCtD
Olmesartan—Diarrhoea—Capecitabine—esophageal cancer	0.00011	0.00179	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—ANXA1—esophageal cancer	0.00011	0.00267	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000109	0.00178	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000109	0.00264	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000109	0.00264	CbGpPWpGaD
Olmesartan—Insomnia—Methotrexate—esophageal cancer	0.000108	0.00176	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—SST—esophageal cancer	0.000107	0.00259	CbGpPWpGaD
Olmesartan—Dizziness—Capecitabine—esophageal cancer	0.000106	0.00173	CcSEcCtD
Olmesartan—Dyspepsia—Methotrexate—esophageal cancer	0.000105	0.00172	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—GHRL—esophageal cancer	0.000104	0.00253	CbGpPWpGaD
Olmesartan—Decreased appetite—Methotrexate—esophageal cancer	0.000104	0.0017	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000103	0.00168	CcSEcCtD
Olmesartan—Fatigue—Methotrexate—esophageal cancer	0.000103	0.00168	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000103	0.0025	CbGpPWpGaD
Olmesartan—Pain—Methotrexate—esophageal cancer	0.000102	0.00167	CcSEcCtD
Olmesartan—Vomiting—Capecitabine—esophageal cancer	0.000102	0.00167	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000102	0.00248	CbGpPWpGaD
Olmesartan—Rash—Capecitabine—esophageal cancer	0.000101	0.00165	CcSEcCtD
Olmesartan—Dermatitis—Capecitabine—esophageal cancer	0.000101	0.00165	CcSEcCtD
Olmesartan—Headache—Capecitabine—esophageal cancer	0.000101	0.00164	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.0001	0.00243	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.0001	0.00242	CbGpPWpGaD
Olmesartan—Feeling abnormal—Methotrexate—esophageal cancer	9.87e-05	0.00161	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—AQP3—esophageal cancer	9.85e-05	0.00239	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Methotrexate—esophageal cancer	9.8e-05	0.0016	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	9.7e-05	0.00235	CbGpPWpGaD
Olmesartan—Nausea—Capecitabine—esophageal cancer	9.56e-05	0.00156	CcSEcCtD
Olmesartan—Urticaria—Methotrexate—esophageal cancer	9.52e-05	0.00155	CcSEcCtD
Olmesartan—Body temperature increased—Methotrexate—esophageal cancer	9.47e-05	0.00154	CcSEcCtD
Olmesartan—Abdominal pain—Methotrexate—esophageal cancer	9.47e-05	0.00154	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	9.44e-05	0.00229	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	9.44e-05	0.00229	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—AQP3—esophageal cancer	9.25e-05	0.00224	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—GNG7—esophageal cancer	9.08e-05	0.0022	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—BLVRB—esophageal cancer	8.92e-05	0.00216	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC52A3—esophageal cancer	8.92e-05	0.00216	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	8.87e-05	0.00215	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	8.87e-05	0.00215	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—AKAP13—esophageal cancer	8.73e-05	0.00211	CbGpPWpGaD
Olmesartan—Asthenia—Methotrexate—esophageal cancer	8.6e-05	0.0014	CcSEcCtD
Olmesartan—Pruritus—Methotrexate—esophageal cancer	8.48e-05	0.00138	CcSEcCtD
Olmesartan—Diarrhoea—Methotrexate—esophageal cancer	8.2e-05	0.00133	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—KMT2D—esophageal cancer	8.15e-05	0.00198	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PDE4D—esophageal cancer	7.98e-05	0.00193	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	7.97e-05	0.00193	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—AKAP13—esophageal cancer	7.93e-05	0.00192	CbGpPWpGaD
Olmesartan—Dizziness—Methotrexate—esophageal cancer	7.92e-05	0.00129	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	7.73e-05	0.00187	CbGpPWpGaD
Olmesartan—Vomiting—Methotrexate—esophageal cancer	7.62e-05	0.00124	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—GNG7—esophageal cancer	7.59e-05	0.00184	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CA1—esophageal cancer	7.58e-05	0.00184	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC10A2—esophageal cancer	7.58e-05	0.00184	CbGpPWpGaD
Olmesartan—Rash—Methotrexate—esophageal cancer	7.56e-05	0.00123	CcSEcCtD
Olmesartan—Dermatitis—Methotrexate—esophageal cancer	7.55e-05	0.00123	CcSEcCtD
Olmesartan—Headache—Methotrexate—esophageal cancer	7.51e-05	0.00122	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—ADCYAP1—esophageal cancer	7.27e-05	0.00176	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PDE4D—esophageal cancer	7.25e-05	0.00176	CbGpPWpGaD
Olmesartan—Nausea—Methotrexate—esophageal cancer	7.12e-05	0.00116	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—CA2—esophageal cancer	6.94e-05	0.00168	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GNG7—esophageal cancer	6.9e-05	0.00167	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	6.78e-05	0.00164	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	6.74e-05	0.00163	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	6.72e-05	0.00163	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CXCL2—esophageal cancer	6.69e-05	0.00162	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—WWOX—esophageal cancer	6.65e-05	0.00161	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.49e-05	0.00157	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ADH7—esophageal cancer	6.45e-05	0.00156	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PLCE1—esophageal cancer	6.45e-05	0.00156	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	6.37e-05	0.00154	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FKBP1A—esophageal cancer	6.32e-05	0.00153	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ANXA1—esophageal cancer	6.22e-05	0.00151	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—WIF1—esophageal cancer	6.18e-05	0.0015	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.1e-05	0.00148	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CXCL2—esophageal cancer	6.08e-05	0.00147	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—SST—esophageal cancer	6.05e-05	0.00147	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—BLVRB—esophageal cancer	5.99e-05	0.00145	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC52A3—esophageal cancer	5.99e-05	0.00145	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GHRL—esophageal cancer	5.9e-05	0.00143	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CSNK1A1—esophageal cancer	5.7e-05	0.00138	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ADH1B—esophageal cancer	5.65e-05	0.00137	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ANXA1—esophageal cancer	5.65e-05	0.00137	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	5.53e-05	0.00134	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—SST—esophageal cancer	5.49e-05	0.00133	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	5.41e-05	0.00131	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TYMP—esophageal cancer	5.4e-05	0.00131	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	5.36e-05	0.0013	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GHRL—esophageal cancer	5.35e-05	0.0013	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PFN1—esophageal cancer	5.33e-05	0.00129	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	5.31e-05	0.00129	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP26A1—esophageal cancer	5.26e-05	0.00127	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—PIK3CA—esophageal cancer	5.25e-05	0.00127	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALOX15—esophageal cancer	5.12e-05	0.00124	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC10A2—esophageal cancer	5.09e-05	0.00123	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CA1—esophageal cancer	5.09e-05	0.00123	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TPI1—esophageal cancer	4.89e-05	0.00118	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTO1—esophageal cancer	4.89e-05	0.00118	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ELMO1—esophageal cancer	4.79e-05	0.00116	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	4.69e-05	0.00114	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALDOB—esophageal cancer	4.68e-05	0.00114	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKAP13—esophageal cancer	4.68e-05	0.00113	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CA2—esophageal cancer	4.66e-05	0.00113	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.55e-05	0.0011	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GAPDH—esophageal cancer	4.51e-05	0.00109	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CRABP1—esophageal cancer	4.47e-05	0.00108	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ADH7—esophageal cancer	4.33e-05	0.00105	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PLCE1—esophageal cancer	4.33e-05	0.00105	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HIST1H2BM—esophageal cancer	4.32e-05	0.00105	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PDE4D—esophageal cancer	4.28e-05	0.00104	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.28e-05	0.00104	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GNG7—esophageal cancer	4.25e-05	0.00103	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GNG7—esophageal cancer	4.07e-05	0.000987	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALDH2—esophageal cancer	3.98e-05	0.000965	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.96e-05	0.000958	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—XIAP—esophageal cancer	3.82e-05	0.000925	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ADH1B—esophageal cancer	3.8e-05	0.00092	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.8e-05	0.00092	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTT1—esophageal cancer	3.79e-05	0.000918	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP2A6—esophageal cancer	3.75e-05	0.000907	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.73e-05	0.000904	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.72e-05	0.0009	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TYMP—esophageal cancer	3.63e-05	0.00088	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CTNNA1—esophageal cancer	3.61e-05	0.000875	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CXCL2—esophageal cancer	3.59e-05	0.00087	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.57e-05	0.000864	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ENO1—esophageal cancer	3.55e-05	0.00086	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTGS1—esophageal cancer	3.55e-05	0.00086	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.55e-05	0.000859	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP26A1—esophageal cancer	3.53e-05	0.000856	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PSME2—esophageal cancer	3.5e-05	0.000848	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PSME1—esophageal cancer	3.5e-05	0.000848	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALOX15—esophageal cancer	3.44e-05	0.000834	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PSME2—esophageal cancer	3.35e-05	0.000812	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PSME1—esophageal cancer	3.35e-05	0.000812	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ANXA1—esophageal cancer	3.34e-05	0.000808	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTO1—esophageal cancer	3.28e-05	0.000795	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TPI1—esophageal cancer	3.28e-05	0.000795	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SST—esophageal cancer	3.25e-05	0.000786	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GHRL—esophageal cancer	3.16e-05	0.000766	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOTCH3—esophageal cancer	3.16e-05	0.000766	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALDOB—esophageal cancer	3.15e-05	0.000763	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FBXW7—esophageal cancer	3.11e-05	0.000754	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.05e-05	0.00074	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GAPDH—esophageal cancer	3.03e-05	0.000734	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP1B1—esophageal cancer	3.02e-05	0.000731	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CRABP1—esophageal cancer	3e-05	0.000728	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GNG7—esophageal cancer	2.86e-05	0.000692	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP19A1—esophageal cancer	2.84e-05	0.000688	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOTCH2—esophageal cancer	2.84e-05	0.000687	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALDH2—esophageal cancer	2.68e-05	0.000648	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—HMOX1—esophageal cancer	2.59e-05	0.000628	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTT1—esophageal cancer	2.55e-05	0.000617	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.54e-05	0.000616	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.54e-05	0.000615	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TGFBR2—esophageal cancer	2.52e-05	0.00061	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP2A6—esophageal cancer	2.52e-05	0.00061	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.51e-05	0.000607	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ABCB1—esophageal cancer	2.49e-05	0.000602	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ENO1—esophageal cancer	2.39e-05	0.000578	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTGS1—esophageal cancer	2.39e-05	0.000578	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.38e-05	0.000577	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SMAD4—esophageal cancer	2.38e-05	0.000577	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PSME2—esophageal cancer	2.35e-05	0.000569	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PSME1—esophageal cancer	2.35e-05	0.000569	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.05e-05	0.000497	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP1B1—esophageal cancer	2.03e-05	0.000491	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HIF1A—esophageal cancer	1.95e-05	0.000472	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP19A1—esophageal cancer	1.91e-05	0.000462	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.88e-05	0.000455	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KDR—esophageal cancer	1.86e-05	0.000452	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOTCH1—esophageal cancer	1.76e-05	0.000425	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HMOX1—esophageal cancer	1.74e-05	0.000422	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.71e-05	0.000414	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ABCB1—esophageal cancer	1.67e-05	0.000405	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CREBBP—esophageal cancer	1.66e-05	0.000403	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CREBBP—esophageal cancer	1.59e-05	0.000386	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—EGFR—esophageal cancer	1.56e-05	0.000379	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.5e-05	0.000362	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NOS3—esophageal cancer	1.49e-05	0.00036	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOS3—esophageal cancer	1.43e-05	0.000345	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTGS2—esophageal cancer	1.36e-05	0.00033	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CA—esophageal cancer	1.36e-05	0.000329	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ERBB2—esophageal cancer	1.33e-05	0.000323	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.26e-05	0.000306	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCND1—esophageal cancer	1.18e-05	0.000285	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CDKN1A—esophageal cancer	1.14e-05	0.000276	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—EP300—esophageal cancer	1.13e-05	0.000274	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CREBBP—esophageal cancer	1.12e-05	0.00027	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EP300—esophageal cancer	1.08e-05	0.000263	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NOS3—esophageal cancer	9.99e-06	0.000242	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MYC—esophageal cancer	9.45e-06	0.000229	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EGFR—esophageal cancer	9.24e-06	0.000224	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTGS2—esophageal cancer	9.14e-06	0.000221	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CA—esophageal cancer	8.37e-06	0.000203	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CA—esophageal cancer	8.02e-06	0.000194	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—esophageal cancer	7.76e-06	0.000188	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—EP300—esophageal cancer	7.6e-06	0.000184	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	5.62e-06	0.000136	CbGpPWpGaD
